Found: 39
Select item for more details and to access through your institution.
Consultations about randomised controlled trials are shorter and less in-depth for socioeconomically disadvantaged patients compared to socioeconomically advantaged patients: qualitative analysis across three trials.
- Published in:
- Trials, 2024, v. 25, n. 1, p. 1, doi. 10.1186/s13063-024-08216-4
- By:
- Publication type:
- Article
Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib.
- Published in:
- Scientific Reports, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41598-023-30148-3
- By:
- Publication type:
- Article
COVID‐19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta‐analysis.
- Published in:
- EJHaem, 2022, v. 3, n. 3, p. 862, doi. 10.1002/jha2.465
- By:
- Publication type:
- Article
Patient and health practitioner views and experiences of a cancer trial before and during COVID-19: qualitative study.
- Published in:
- Trials, 2022, v. 23, n. 1, p. 1, doi. 10.1186/s13063-022-06453-z
- By:
- Publication type:
- Article
Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells.
- Published in:
- Scientific Reports, 2021, v. 11, n. 1, p. 1, doi. 10.1038/s41598-021-82609-2
- By:
- Publication type:
- Article
Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-020-20822-9
- By:
- Publication type:
- Article
A five‐year follow‐up of untreated patients with chronic lymphocytic leukaemia treated with ofatumumab and chlorambucil: final analysis of the Complement 1 phase 3 trial.
- Published in:
- British Journal of Haematology, 2020, v. 190, n. 5, p. 736, doi. 10.1111/bjh.16625
- By:
- Publication type:
- Article
A phase II study to assess the safety and efficacy of the dual mTORC1/2 inhibitor vistusertib in relapsed, refractory DLBCL.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Central nervous system plasmablastic lymphoma evolving from polyclonal plasmacytosis.
- Published in:
- 2018
- By:
- Publication type:
- Case Study
Guideline for the treatment of chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 3, p. 344, doi. 10.1111/bjh.15460
- By:
- Publication type:
- Article
A multi‐centre phase I trial of the PARP inhibitor olaparib in patients with relapsed chronic lymphocytic leukaemia, T‐prolymphocytic leukaemia or mantle cell lymphoma.
- Published in:
- British Journal of Haematology, 2018, v. 182, n. 3, p. 429, doi. 10.1111/bjh.14793
- By:
- Publication type:
- Article
An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects.
- Published in:
- 2018
- By:
- Publication type:
- Abstract
Genome-wide association analysis of chronic lymphocytic leukaemia, Hodgkin lymphoma and multiple myeloma identifies pleiotropic risk loci.
- Published in:
- Scientific Reports, 2017, p. 41071, doi. 10.1038/srep41071
- By:
- Publication type:
- Article
NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome.
- Published in:
- British Journal of Haematology, 2016, v. 175, n. 1, p. 43, doi. 10.1111/bjh.14177
- By:
- Publication type:
- Article
Correction: Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.
- Published in:
- 2016
- By:
- Publication type:
- Correction Notice
BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.
- Published in:
- PLoS ONE, 2015, v. 10, n. 10, p. 1, doi. 10.1371/journal.pone.0142379
- By:
- Publication type:
- Article
Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins.
- Published in:
- Experimental Hematology & Oncology, 2015, v. 4, n. 1, p. 1, doi. 10.1186/s40164-015-0004-3
- By:
- Publication type:
- Article
Immunohistochemical analysis indicates that the anatomical location of B-cell non-Hodgkin's lymphoma is determined by differentially expressed chemokine receptors, sphingosine-1-phosphate receptors and integrins.
- Published in:
- Experimental Hematology & Oncology, 2015, v. 4, n. 1, p. 1, doi. 10.1186/s40164-015-0004-3
- By:
- Publication type:
- Article
Selective IAP inhibition results in sensitization of unstimulated but not CD40-stimulated chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis.
- Published in:
- Pharmacology Research & Perspectives, 2014, v. 2, n. 6, p. n/a, doi. 10.1002/prp2.81
- By:
- Publication type:
- Article
Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach.
- Published in:
- British Journal of Haematology, 2014, v. 167, n. 4, p. 565, doi. 10.1111/bjh.13006
- By:
- Publication type:
- Article
Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2014, v. 167, n. 3, p. 346, doi. 10.1111/bjh.13043
- By:
- Publication type:
- Article
Motility and trafficking in B-cell non-Hodgkin's lymphoma (Review).
- Published in:
- International Journal of Oncology, 2014, v. 45, n. 1, p. 5, doi. 10.3892/ijo.2014.2395
- By:
- Publication type:
- Article
A genome-wide association study identifies multiple susceptibility loci for chronic lymphocytic leukemia.
- Published in:
- Nature Genetics, 2014, v. 46, n. 1, p. 56, doi. 10.1038/ng.2843
- By:
- Publication type:
- Article
Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia.
- Published in:
- BMC Medical Research Methodology, 2013, v. 13, n. 1, p. 1, doi. 10.1186/1471-2288-13-87
- By:
- Publication type:
- Article
Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia.
- Published in:
- 2013
- By:
- Publication type:
- journal article
The gene expression signature associated with TP53 mutation/deletion in chronic lymphocytic leukaemia is dominated by the under-expression of TP53 and other genes on chromosome 17p.
- Published in:
- British Journal of Haematology, 2013, v. 160, n. 1, p. 53, doi. 10.1111/bjh.12092
- By:
- Publication type:
- Article
Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2012, v. 159, n. 5, p. 541, doi. 10.1111/bjh.12067
- By:
- Publication type:
- Article
Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.
- Published in:
- European Journal of Haematology, 2011, v. 87, n. 4, p. 372, doi. 10.1111/j.1600-0609.2011.01667.x
- By:
- Publication type:
- Article
A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2011, v. 152, n. 5, p. 570, doi. 10.1111/j.1365-2141.2010.08317.x
- By:
- Publication type:
- Article
Screened selection design for randomised phase II oncology trials: an example in chronic lymphocytic leukaemia.
- Published in:
- 2011
- By:
- Publication type:
- Abstract
Ribosome-associated nucleophosmin 1: increased expression and shuttling activity distinguishes prognostic subtypes in chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2010, v. 148, n. 4, p. 534, doi. 10.1111/j.1365-2141.2009.07979.x
- By:
- Publication type:
- Article
A genome-wide association study identifies six susceptibility loci for chronic lymphocytic leukemia.
- Published in:
- Nature Genetics, 2008, v. 40, n. 10, p. 1204, doi. 10.1038/ng.219
- By:
- Publication type:
- Article
The development of sarcoidosis with the use of alemtuzumab – clues to T-cell immune reconstitution.
- Published in:
- 2007
- By:
- Publication type:
- Letter
Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia.
- Published in:
- Oncogene, 2005, v. 24, n. 45, p. 6855, doi. 10.1038/sj.onc.1208895
- By:
- Publication type:
- Article
Down-regulation of BCL-2 and its prevention by interleukin-4 in cultured chronic lymphocytic leukaemia cells is a methodological artefact caused by failure of protein detection/extraction following the onset of cell death.
- Published in:
- 2004
- By:
- Publication type:
- Letter
The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes.
- Published in:
- Oncogene, 2004, v. 23, n. 10, p. 1911, doi. 10.1038/sj.onc.1207318
- By:
- Publication type:
- Article
Mechanism of action of purine analogues in chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2003, v. 121, n. 5, p. 692, doi. 10.1046/j.1365-2141.2003.04336.x
- By:
- Publication type:
- Article
Cytoprotective antioxidant activity of serum albumin and autocrine catalase in chronic lymphocytic leukaemia.
- Published in:
- British Journal of Haematology, 2002, v. 116, n. 2, p. 316, doi. 10.1046/j.1365-2141.2002.03280.x
- By:
- Publication type:
- Article